Latest Research Collaboration News

White Energy Company Limited has kicked off core drilling at its Specimen Hill Project in Queensland while continuing extensive geochemical exploration at its Tindal Project in the Northern Territory. Meanwhile, its innovative Binderless Coal Briquetting technology is progressing through commercial trials in South Africa.

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Metallium Ltd has marked a pivotal quarter with a U.S. Department of Defense contract award, strategic partnerships, and progress on its Texas Flash Joule Heating plant, positioning itself as a key player in the U.S. critical metals recovery sector.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Cobram Estate Olives Limited has reported record financial results for FY2025, driven by strong sales growth in Australia and a doubling of branded sales in the USA. The company is shifting its capital expenditure focus to expand its Californian operations while maintaining sustainable growth in Australia.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Latitude 66 has agreed to sell its 17.5% interest in the Greater Duchess Joint Venture for an upfront A$2 million, with potential for further contingent payments, while progressing exploration in Australia and Finland amid regulatory challenges.